- Related Products
MedEx answers any queries you might have regarding Jakavi-15 purchase, shipping and payment terms.
Feel free to contact support through inquiry form, MedeEx is fully dedicated towards your needs 24/7.
Principle of action.
Enlarged spleen is one of the characteristics of myelofibrosis. It is a bone marrow disorder, in which it is replaced by the scar tissue. At that, the bone marrow stops producing the normal blood cell, and as a result, the liver increases significantly.
Erythremia is a state, in which the bone marrow produces too many blood vessels. As a result, the blood thicken. Jakavi 15 mg can relieve such symptoms as fever, night sweats, bone pain and weight loss, reduction in the size of liver and the amount of red bloods cells, formed in the patients by means of inhibiting JAK-kinases (JAK1 and JAK2). Thus, it can lower the risk of serious complications on the part of circulatory and vascular system.
In 2011, Ruxolitinib was approved by FDA for the treatment of myelofibrosis of moderate and high degree of risk (based on the results of the studies COMFORT I and II). In 2014, the drug was approved for the treatment of erythremia (based on the results of the primary RESPONSE).
Way of use.
The dose of Jakavi 15 mg depends on the patient’s platelet count. Therefore, you should take a blood test before the beginning of treatment, so that the doctor can choose the optimal dosage for you.
The recommended initial dose for the treatment of myelofibrosis is 15 mg twice a day; in case of erythremia, you should take 10 mg twice a day. The maximum dose is 25 mg twice a day. During the treatment, your dose can be decreased or increased depending on the result of the blood test, kidney/liver disorders or treatment with the other drugs.
If you’re on dialysis, take one dose or two separate doses only in the days of dialysis (after the end of procedure). You should take the drug every day at the same time, irrespective of the mealtime.
Jakavi 15 mg can cause the following side effects: pancitopenia, anemia, thrombocytopenia, increased ALT level, vertigo, high cholesterol, headache, opportunistic infections, weight gain, etc.
If the treatment is stopped abruptly, Ruxolitinib can exacerbate the symptoms of disease. Therefore, you should strictly follow the instructions of your doctor.